Rising oil prices and global growth threats stemming from the Middle East conflict and IMF's downgraded forecasts could increase Bioventus's operational costs and potentially dampen overall healthcare spending, impacting demand for its medical devices.

A strong U.S. job market and dipping unemployment suggest robust consumer confidence and potentially higher disposable income, which could support consumer-driven healthcare spending and demand for Bioventus's musculoskeletal and pain treatment solutions.

Implicit inflationary pressures, driven by global events, could affect Bioventus through increased costs of raw materials, energy, and labor, making the company's ability to maintain or expand gross margins crucial for profitability. The company's 2025 guidance included a $5 million impact from tariffs and foreign exchange.